title: Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
abstract: OBJECTIVE
  To examine the hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates.
  
  
  METHODS
  Nested case-control analysis within a primary care cohort of about 6 million people in the UK, with prospectively recorded information on prescribing of bisphosphonates.
  
  
  METHODS
  UK General Practice Research Database cohort.
  
  
  METHODS
  Men and women aged 40 years or over-2954 with oesophageal cancer, 2018 with gastric cancer, and 10 641 with colorectal cancer, diagnosed in 1995-2005; five controls per case matched for age, sex, general practice, and observation time.
  
  
  METHODS
  Relative risks for incident invasive cancers of the oesophagus, stomach, and colorectum, adjusted for smoking, alcohol, and body mass index.
  
  
  RESULTS
  The incidence of oesophageal cancer was increased in people with one or more previous prescriptions for oral bisphosphonates compared with those with no such prescriptions (relative risk 1.30, 95% confidence interval 1.02 to1.66; P=0.02). Risk of oesophageal cancer was significantly higher for 10 or more prescriptions (1.93, 1.37 to 2.70) than for one to nine prescriptions (0.93, 0.66 to 1.31) (P for heterogeneity=0.002), and for use for over 3 years (on average, about 5 years: relative risk v no prescription, 2.24, 1.47 to 3.43). Risk of oesophageal cancer did not differ significantly by bisphosphonate type, and risk in those with 10 or more bisphosphonate prescriptions did not vary by age, sex, smoking, alcohol intake, or body mass index; by diagnosis of osteoporosis, fracture, or upper gastrointestinal disease; or by prescription of acid suppressants, non-steroidal anti-inflammatory drugs, or corticosteroids. Cancers of the stomach and colorectum were not associated with prescription of bisphosphonate: relative risks for one or more versus no prescriptions were 0.87 (0.64 to 1.19) and 0.87 (0.77 to 1.00). The specificity of the association for oesophageal cancer argues against methodological problems in the selection of cases and controls or in the analysis.
  
  
  CONCLUSIONS
  The risk of oesophageal cancer increased with 10 or more prescriptions for oral bisphosphonates and with prescriptions over about a five year period. In Europe and North America, the incidence of oesophageal cancer at age 60-79 is typically 1 per 1000 population over five years, and this is estimated to increase to about 2 per 1000 with five years' use of oral bisphosphonates.
authors.affiliation: Cancer Epidemiology Unit, University of Oxford, Oxford OX3 7LF. jane.green@ceu.ox.ac.uk
authors.forename: Jane
authors.initials: J
authors.lastname: Green
authors.forename: Gabriela
authors.initials: G
authors.lastname: Czanner
authors.forename: Gillian
authors.initials: G
authors.lastname: Reeves
authors.forename: Joanna
authors.initials: J
authors.lastname: Watson
authors.forename: Lesley
authors.initials: L
authors.lastname: Wise
authors.forename: Valerie
authors.initials: V
authors.lastname: Beral
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000139:chemically induced; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004938:Esophageal Neoplasms / Q000139:chemically induced; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000139:chemically induced
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references.citation: Eur J Clin Pharmacol. 2007 Sep;63(9):843-9
references.pmid: 17598097
references.citation: Ann Intern Med. 2008 Feb 5;148(3):197-213
references.pmid: 18087050
references.citation: Osteoporos Int. 2007 Aug;18(8):1023-31
references.pmid: 17308956
references.citation: JAMA. 1996 Nov 6;276(17):1404-8
references.pmid: 8892715
references.citation: Curr Opin Rheumatol. 2009 Jul;21(4):363-8
references.pmid: 19412101
references.citation: JAMA. 2010 Aug 11;304(6):657-63
references.pmid: 20699457
references.citation: BMJ. 2007 Dec 1;335(7630):1134
references.pmid: 17986716
references.citation: Calcif Tissue Int. 2010 Feb;86(2):110-5
references.pmid: 19957165
references.citation: Ann Intern Med. 2008 Sep 16;149(6):404-15
references.pmid: 18794560
references.citation: Osteoporos Int. 2008 Apr;19(4):399-428
references.pmid: 18266020
references.citation: N Engl J Med. 2009 Jan 1;360(1):89-90
references.pmid: 19118315
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523
references.pmid: 18254053
references.citation: N Engl J Med. 2009 Apr 23;360(17):1789; author reply 1791-2
references.pmid: 19387022
references.citation: Maturitas. 2009 Feb 20;62(2):105-8
references.pmid: 19135323
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155
references.pmid: 18253985
references.citation: J Natl Cancer Inst. 2009 Mar 4;101(5):296-305
references.pmid: 19244173
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003376
references.pmid: 18254018
references.citation: N Engl J Med. 2008 Apr 3;358(14):1474-82
references.pmid: 18385499
references.citation: Dig Dis Sci. 2010 Dec;55(12):3404-7
references.pmid: 20397052
references.citation: Pharmacotherapy. 2003 May;23(5):686-9
references.pmid: 12741446
references.citation: Br J Cancer. 2010 Mar 2;102(5):799-802
references.pmid: 20160722
references.citation: N Engl J Med. 2009 Apr 23;360(17):1789-90; author reply 1791-2
references.pmid: 19391255
references.citation: Br J Clin Pharmacol. 2010 Jan;69(1):4-14
references.pmid: 20078607